Indegene Ltd.
NSE: INDGN · Healthcare Research, Analytics & Technology
Snapshot
Unlock Indegene Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Indegene Limited is a life sciences commercialisation company that provides technology-led solutions to biopharmaceutical, emerging biotech, and medical device firms. The company supports clients across the product life cycle, from clinical development to market entry and commercial growth.
Business Model
The company generates revenue by providing enterprise-level commercial, medical, and clinical solutions, alongside its proprietary NEXT technology platforms. It operates as a strategic partner to life sciences companies, helping them navigate complex regulatory and market environments.
Growth Outlook
Growth is driven by the increasing demand for digital transformation and commercialisation support within the global life sciences sector. The company continues to leverage its technology platforms to scale operations and enhance client impact.
Key Risks
- Client Concentration. A significant portion of revenue is derived from a limited number of large biopharmaceutical clients, making the company vulnerable to changes in their R&D budgets.
- Regulatory Compliance. The company must adhere to stringent global healthcare regulations, and any failure to maintain compliance could lead to legal penalties and reputational damage.
- Technological Obsolescence. Rapid advancements in AI and digital health technologies require continuous investment to remain competitive against evolving industry standards.
- Geopolitical and Currency Risk. As an international operator, the company is exposed to fluctuations in foreign exchange rates and geopolitical instability in the markets where its clients operate.
Start your research today
Unlock AI insights, financials, peers and live data on Indegene Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹3,813 Cr
TTM · consolidated
NET PROFIT
₹401 Cr
TTM · consolidated
EPS
₹16.71
TTM · consolidated
RETURN ON EQUITY
13.9%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
17.4%
TTM · consolidated
P/E
36.0x
Q1 FY27 · consolidated
EV/EBITDA
19.8x
Q1 FY27 · consolidated
EBITDA MARGIN
18.8%
TTM · consolidated
NET PROFIT MARGIN
10.9%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Healthcare Research, Analytics & Technology
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Indegene Ltd.INDGN | ₹14,493 Cr | 36.00 | 19.80 | 30.4% | 18.8% | 13.9% | 17.4% | +10.6% |
Syngene International Ltd.SYNGENE | ₹15,969 Cr | 71.93 | 17.87 | -3.4% | 24.5% | 4.6% | 6.2% | -39.8% |
Suven Life Sciences LimitedSUVEN | ₹10,681 Cr | -25.39 | -30.90 | 17.3% | -557.4% | -100.5% | -99.8% | +78.6% |
Vimta LabsVIMTALABS | ₹2,839 Cr | 35.59 | 18.05 | 15.2% | 37.3% | 19.1% | 24.1% | -20.2% |
Fabtech Technologies LimitedFABTECH | ₹668 Cr | 10.87 | 9.14 | — | 16.3% | 11.6% | 14.1% | — |
Take SolutionsTAKE | ₹204 Cr | 16.07 | 32.77 | — | 7.4% | 49.8% | 24.2% | +27.3% |
As of Q1 FY27
Financials
Indegene Ltd.
NSE: INDGN · Healthcare Research, Analytics & Technology
Snapshot
Unlock Indegene Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Indegene Limited is a life sciences commercialisation company that provides technology-led solutions to biopharmaceutical, emerging biotech, and medical device firms. The company supports clients across the product life cycle, from clinical development to market entry and commercial growth.
Business Model
The company generates revenue by providing enterprise-level commercial, medical, and clinical solutions, alongside its proprietary NEXT technology platforms. It operates as a strategic partner to life sciences companies, helping them navigate complex regulatory and market environments.
Growth Outlook
Growth is driven by the increasing demand for digital transformation and commercialisation support within the global life sciences sector. The company continues to leverage its technology platforms to scale operations and enhance client impact.
Key Risks
- Client Concentration. A significant portion of revenue is derived from a limited number of large biopharmaceutical clients, making the company vulnerable to changes in their R&D budgets.
- Regulatory Compliance. The company must adhere to stringent global healthcare regulations, and any failure to maintain compliance could lead to legal penalties and reputational damage.
- Technological Obsolescence. Rapid advancements in AI and digital health technologies require continuous investment to remain competitive against evolving industry standards.
- Geopolitical and Currency Risk. As an international operator, the company is exposed to fluctuations in foreign exchange rates and geopolitical instability in the markets where its clients operate.
Start your research today
Unlock AI insights, financials, peers and live data on Indegene Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹3,813 Cr
TTM · consolidated
NET PROFIT
₹401 Cr
TTM · consolidated
EPS
₹16.71
TTM · consolidated
RETURN ON EQUITY
13.9%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
17.4%
TTM · consolidated
P/E
36.0x
Q1 FY27 · consolidated
EV/EBITDA
19.8x
Q1 FY27 · consolidated
EBITDA MARGIN
18.8%
TTM · consolidated
NET PROFIT MARGIN
10.9%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Healthcare Research, Analytics & Technology
As of Q1 FY27